Valuation: HighTide Therapeutics, Inc.

Market Cap 1.35B 1.57B 200M 175M 160M 150M 284M 19.05B 288M 1.92B 749M 9.35B 751M 735M 32.28B P/E 2024
-1.41x
P/E 2025 -5.19x
Enterprise Value 979M 1.13B 145M 126M 116M 108M 205M 13.76B 208M 1.39B 541M 6.76B 543M 531M 23.32B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
44.17%
Yield 2024 *
-
Yield 2025 -
1 day+1.48%
1 week+1.86%
Current month+2.24%
1 month-11.33%
3 months-15.95%
6 months-9.57%
Current year-7.12%
1 week 2.67
Extreme 2.67
2.88
1 month 2.28
Extreme 2.28
3.2
Current year 1.8
Extreme 1.8
4.72
1 year 1.8
Extreme 1.8
4.72
3 years 0.72
Extreme 0.72
13.18
5 years 0.72
Extreme 0.72
13.18
10 years 0.72
Extreme 0.72
13.18
Manager TitleAgeSince
Chief Executive Officer 56 31/12/2010
Director of Finance/CFO 57 30/11/2022
Chief Tech/Sci/R&D Officer - 01/02/2026
Director TitleAgeSince
Director/Board Member 68 29/11/2020
Director/Board Member 61 -
Chairman 56 -
Date Insider Type Main position Quantity % Market Cap.
04-29Other

Director

1,800,000 0.3151%
03-31Other

Chief Executive Officer

8,325,618 1.4572%
31/03/25Other

Chief Executive Officer

3,960,550 0.7694%
Change 5-day change 1-year change 3-year change Capi.($)
+1.48%+1.86%+0.74% - 200M
+0.68%+5.92%+77.86%+139.22% 59.1B
+2.32%+5.03%+75.26%+91.40% 55.19B
+3.86%+6.93%-11.32%-9.53% 24.67B
+4.30%+7.95%+14.11%+437.83% 24.19B
+4.74%+13.68%+43.36%-4.67% 19.69B
-0.29%+9.78%+43.90%-28.41% 17.56B
0.00%+20.78%+186.15%+361.42% 16.22B
+6.72%+19.38%+37.85% - 14.84B
+3.50%+1.97%+21.02%+191.95% 14.04B
Average +2.73%+7.90%+48.89%+147.40% 24.57B
Weighted average by Cap. +2.46%+6.47%+58.28%+136.98%

Financials

2024 2025
Net sales - -
Net income -382M -442M -56.39M -49.21M -45.22M -42.14M -79.92M -5.37B -81.27M -542M -211M -2.64B -212M -207M -9.1B -245M -284M -36.18M -31.57M -29.01M -27.04M -51.28M -3.44B -52.15M -348M -135M -1.69B -136M -133M -5.84B
Net Debt -413M -478M -60.97M -53.21M -48.89M -45.56M -86.41M -5.8B -87.88M -586M -228M -2.85B -229M -224M -9.84B -376M -435M -55.53M -48.46M -44.53M -41.5M -78.7M -5.29B -80.03M -534M -208M -2.59B -208M -204M -8.96B
Logo HighTide Therapeutics, Inc.
HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The Company has developed a product pipeline of multiple product candidates in-house, covering many indications in metabolic and digestive diseases among which, some are at clinical-stage. The Company’s core product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases. The Company conducts operations in the United States, Mainland China, Hong Kong and Australia.
Employees
51
Date Price Change Volume
03/07/26 HK$2.740 +1.48% 68,500
02/07/26 HK$2.700 +0.75% 52,500
30/06/26 HK$2.680 -3.94% 75,500
29/06/26 HK$2.790 +3.72% 127,550

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 2511 Stock